Decreased Levels of SARS-CoV-2 Fusion-Inhibitory Antibodies in the Serum of Aged COVID-19 Patients.

Autor:	Malézieux-Picard A; Division of Internal Medicine for the Aged, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, 3 Chemin du Pont-Bochet, 1226 Thônex, Switzerland., Abdul F; Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Rue Michel-Servet 1, 1206 Geneva, Switzerland., Herrmann FR; Division of Geriatrics and Rehabilitation, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, 3 Chemin du Pont-Bochet, 1226 Thônex, Switzerland., Caillon A; Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Rue Michel-Servet 1, 1206 Geneva, Switzerland., Ribaux P; Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Rue Michel-Servet 1, 1206 Geneva, Switzerland., Cambet Y; Division of Laboratory Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland., Yerly S; Division of Laboratory Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland.; Laboratory of Virology, Geneva Center for Emerging Viral Diseases, Geneva University Hospitals, 1205 Geneva, Switzerland., Baggio S; Division of Prison Health, Geneva University Hospitals, University of Geneva, 1206 Geneva, Switzerland.; Institute of Primary Health Care (BIHAM), University of Bern, 3012 Bern, Switzerland., Vernaz N; Medical Directorate, Finance Directorate, Geneva University Hospitals, 1205 Geneva, Switzerland., Zekry D; Division of Internal Medicine for the Aged, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, 3 Chemin du Pont-Bochet, 1226 Thônex, Switzerland., Krause KH; Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Rue Michel-Servet 1, 1206 Geneva, Switzerland.; Division of Infectious Diseases, Geneva University Hospitals, 1205 Geneva, Switzerland., Preynat-Seauve O; Department of Diagnostics, Geneva University Hospitals, 1205 Geneva, Switzerland.; Department of Medicine, Medical School, University of Geneva, 1205 Geneva, Switzerland., Prendki V; Division of Internal Medicine for the Aged, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, 3 Chemin du Pont-Bochet, 1226 Thônex, Switzerland.; Division of Infectious Diseases, Geneva University Hospitals, 1205 Geneva, Switzerland.
Jazyk:	angličtina
Zdroj:	Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2022 Jul 28; Vol. 12 (8). Date of Electronic Publication: 2022 Jul 28.
DOI:	10.3390/diagnostics12081813
Abstrakt:	Background: The SARS-CoV-2 pandemic was particularly devastating for elderly people, and the underlying mechanisms of the disease are still poorly understood. In this study, we investigated fusion inhibitory antibodies (fiAbs) in elderly and younger COVID-19 patients and analyzed predictive factors for their occurrence. Methods: Data and samples were collected in two cohorts of hospitalized patients. A fusion assay of SARS-CoV-2 spike-expressing cells with ACE2-expressing cells was used to quantify fiAbs in the serum of patients. Results: A total of 108 patients (52 elderly (mean age 85 ± 7 years); 56 young (mean age 52 ± 10 years)) were studied. The concentrations of fiAbs were lower in geriatric patients, as evidenced at high serum dilutions (1/512). The association between fiAbs and anti-Spike Ig levels was weak (correlation coefficient < 0.3), but statistically significant. Variables associated with fusion were the delay between the onset of symptoms and testing (HR = −2.69; p < 0.001), clinical frailty scale (HR = 4.71; p = 0.035), and WHO severity score (HR = −6.01, p = 0.048). Conclusions: Elderly patients had lower fiAbs levels after COVID-19 infection. The decreased fiAbs levels were associated with frailty.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF